Saturday, May 09, 2015 3:04:40 PM
NEW YORK, May 4, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq: NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today that the Company's management and experts will present at multiple conferences in May and early June.
Research Seminar Series, Li Ka Shing Knowledge Institute (LKSKI)
Date and Time: Thursday, May 7, 2015, 1:00 PM ET
Venue: St. Michael's Hospital, Toronto, Canada
Website: http://www.stmichaelshospital.com/knowledgeinstitute/education.php
Presenter: Dr. Douglas Losordo, Chief Medical Officer
Topic: Cell Therapy for Cardiovascular Disease
World Stem Cells and Regenerative Medicine Congress
Date and Time: Wednesday, May 20, 2015, 3:30 PM GMT
Venue: Business Design Centre, London
Website: http://www.terrapinn.com/conference/stem-cells/
Presenter: Dr. Robert Preti, President of PCT, Chief Scientific Officer of NeoStem
Topic: Accelerating Time To Market: Development and manufacturing considerations for cell therapy product commercialization
2015 Marcum MicroCap Conference
Date and Time: Thursday, May 28, 2015, 9:30 AM ET
Venue: Grand Hyatt New York, NY
Website: http://www.marcumllp.com/MicroCap
Presenter: Dr. David J. Mazzo, Chief Executive Officer
Topic: Company Presentation
Webcast: www.neostem.com/investors/investor-events/
12th International Symposium on Stem Cell Therapy & Cardiovascular Innovations
Date and Time: Thursday, May 28, 2015, 11:18 AM CET
Venue: Aula Magna. Pabellón Docente. Hospital Universitario Gregorio Marañón, Madrid, Spain
Website: http://www.cardiovascularcelltherapy.com/
Presenter: Dr. Douglas Losordo, Chief Medical Officer
Topic: Cell based therapies to prevent and cure heart failure. More than an adventure?
International Society for Cell Therapy 2015 Annual Meeting
Date and Time: Friday, May 29, 2015, 12:45 PM PT
Venue: Caesars Palace, Las Vegas, Nevada
Website: http://www.celltherapysociety.org/
Workshop Participant: Dr. Jacob Ceccarelli, Biotechnology Engineer, PCT
Topic: Corporate Tutorial – Fresenius Kabi
2015 ASCO Annual Meeting
Date and Time: Monday, June 1, 2015, 1:15 – 4:15 PM CT
Venue: McCormick Place, Chicago, Illinois
Website: http://am.asco.org/
Presenter: Dr. Robert O. Dillman, Vice President, Oncology
Poster: Phase III multicenter trial of eltrapuldencel-T: Autologous dendritic cells loaded with irradiated autologous tumor cells (DC-TC) in granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma (Intus trial)
http://www.streetinsider.com/Press+Releases/NeoStem+to+Present+at+Multiple+May+and+June+Conferences/10515324.html
Recent LSTA News
- Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer • GlobeNewswire Inc. • 05/20/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/10/2024 04:15:16 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:13:47 PM
- Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events • GlobeNewswire Inc. • 05/08/2024 12:00:00 PM
- Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma • GlobeNewswire Inc. • 04/23/2024 11:30:00 AM
- Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma • GlobeNewswire Inc. • 04/09/2024 12:30:00 PM
- Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Lisata Therapeutics to Present at BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
- Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Lisata Therapeutics to Present at NobleCon19 Investor Conference • GlobeNewswire Inc. • 11/28/2023 09:05:00 PM
- Lisata Therapeutics Announces Participation in Upcoming Conferences in November • GlobeNewswire Inc. • 11/09/2023 09:05:00 PM
- Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/02/2023 08:05:00 PM
- Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time • GlobeNewswire Inc. • 10/26/2023 12:00:00 PM
- Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide • GlobeNewswire Inc. • 10/24/2023 12:00:00 PM
- Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 10/17/2023 12:00:00 PM
- Lisata Therapeutics Announces Participation in Upcoming Conferences in October • GlobeNewswire Inc. • 09/28/2023 12:00:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM